Role of old antimicrobial agents in the management of urinary tract infection

Expert Review of Clinical Pharmacology

Volumn 9, Issue 8, 2016, Pages 1047-1056

  El Sakka, Noha ^a   Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

cycloserine; fosfomycin; mandelic acid; mecillinam; methenamine; nitroxoline; Temocillin; urinary tract infection

Indexed keywords

CYCLOSERINE; FOSFOMYCIN; MANDELIC ACID; MECILLINAM; METHENAMINE; NITROXOLINE; TEMOCILLIN; URINARY TRACT ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG TOLERANCE; HUMAN; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION; ANIMAL; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84979265970     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1189325     Document Type: Review

References (80)

1. A.Matagne, J.Lamotte-Brasseur, G.Dive, et al. Interactions between active-site-serine beta-lactamases and compounds bearing a methoxy side chain on the alpha-face of the beta-lactam ring: kinetic and molecular modelling studies. Biochem J. 1993;293(Pt 3):607–611.
2. R.C.Spencer Temocillin. J Antimicrob Chemother. 1990;26(6):735–737.
3. H.Rodriguez-Villalobos, V.Malaviolle, J.Frankard, et al. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2006;57(4):771–774.
4. D.M.Livermore, R.Hope, E.J.Fagan, et al. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 2006;57(5):1012–1014.
5. J.M.Andrews, B.Testing. BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother. 2008;62(2):256–278.
6. Y.Glupczynski, T.D.Huang, C.Berhin, et al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis. 2007;26(11):777–783.
7. J.M.Adams-Haduch, B.A.Potoski, H.E.Sidjabat, et al. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2009;53(6):2700–2701.
8. D.M.Livermore, M.Warner, S.Mushtaq, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–419.• Presents UK data of antimicrobial susceptibility of carbapenem producers.
9. N.Woodford, R.Pike, D.Meunier, et al. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother. 2014;69(2):564–567.
10. P.C.Fuchs, A.L.Barry, C.Thornsberry, et al. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol. 1985;4(1):30–33.
11. T.D.Huang, L.Poirel, P.Bogaerts, et al. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers. J Antimicrob Chemother. 2014;69(2):445–450.
12. R.De Jongh, R.Hens, V.Basma, et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother. 2008;61(2):382–388.• A well conducted in vitro study on the PK/PD of temocillin.
13. P.F.Laterre, X.Wittebole, S.Van de Velde, et al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother. 2015;70(3):891–898.
14. I.Balakrishnan, F.M.Awad-El-Kariem, A.Aali, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011;66(11):2628–2631.
15. N.D.Gupta, R.E.Smith, I.Balakrishnan. Clinical efficacy of temocillin. J Antimicrob Chemother. 2009;64(2):431–433.
16. H.W.Mittermayer. Influence of temocillin on human bowel flora. Drugs. 1985;29(Suppl 5):43–48.
17. D.Hendlin, E.O.Stapley, M.Jackson, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122–123.
18. G.Kahlmeter. Eco.Sens. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51(1):69–76.• An extensive survey across Europe illustrating the microbiological profile of urinary pathogens.
19. P.Hedman, O.Ringertz, M.Lindstrom, et al. The origin of Staphylococcus saprophyticus from cattle and pigs. Scand J Infect Dis. 1993;25(1):57–60.
20. A.Marchese, L.Gualco, E.A.Debbia, et al. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003;22(Suppl 2):53–59.
21. K.Takahashi, H.Kanno. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;26(5):789–791.
22. J.Rodriguez-Bano, J.C.Alcala, J.M.Cisneros, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168(17):1897–1902.
23. H.Pullukcu, M.Tasbakan, O.R.Sipahi, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29(1):62–65.
24. K.S.Ko, J.Y.Suh, K.R.Peck, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis. 2007;58(1):111–115.
25. M.E.Falagas, A.C.Kastoris, A.M.Kapaskelis, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50.• A systematic review evaluating the antimicrobial activity of fosfomycin.
26. A.Endimiani, G.Patel, K.M.Hujer, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54(1):526–529.
27. G.C.Schito. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003;22(Suppl 2):79–83.
28. D.S.Reeves. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34(6):853–858.
29. B.Ode, S.Haidl, B.Hoffstedt, et al. Fosfomycin versus ampicillin in the treatment of acute pyelonephritis. Chemioterapia. 1988;7(2):96–100.
30. M.A.Minassian, D.A.Lewis, D.Chattopadhyay, et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998;10(1):39–47.
31. G.Elhanan, H.Tabenkin, R.Yahalom, et al. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother. 1994;38(11):2612–2614.
32. M.E.Falagas, E.K.Vouloumanou, A.G.Togias, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862–1877.•• A comprehensive meta-analysis on the clinical effectiveness of fosfomycin.
33. J.B.Boerema, F.T.Willems. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection. 1990;18(Suppl 2):S80–S88.
34. H.Kumon. Management of biofilm infections in the urinary tract. World J Surg. 2000;24(10):1193–1196.
35. A.Marchese, M.Bozzolasco, L.Gualco, et al. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents. 2003;22(Suppl 2):95–100.
36. S.Dewar, L.C.Reed, R.J.Koerner. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother. 2014;69(2):303–308.
37. W.Sougakoff, V.V.Jarlier. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother. 2000;46(Suppl A):9–14.
38. P.Bemer-Melchior, L.Gilly, K.Jugroot-Klotz, et al. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital]. Pathol Biol (Paris). 1995;43(9):760–765.
39. M.Wootton, T.R.Walsh, L.Macfarlane, et al. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2010;65(1):79–81.
40. K.Thomas, M.J.Weinbren, M.Warner, et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother. 2006;57(2):367–368.
41. D.M.Livermore, S.Mushtaq, T.Nguyen, et al. Strategies to overcome extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases in shigellae. Int J Antimicrob Agents. 2011;37(5):405–409.
42. E.C.Marrs, K.M.Day, J.D.Perry. In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. J Antimicrob Chemother. 2014;69(10):2873–2875.
43. J.D.Perry, S.H.Naqvi, I.A.Mirza, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother. 2011;66(10):2288–2294.
44. F.Jansaker, N.Frimodt-Moller, I.Sjogren, et al. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother. 2014;69(3):769–772.
45. E.Titelman, A.Iversen, M.Kalin, et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist. 2012;18(2):189–192.
46. L.E.Nicolle, M.R.Mulvey. Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis. 2007;39(8):748–749.
47. A.Soraas, A.Sundsfjord, S.B.Jorgensen, et al. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One. 2014;9(1):e85889.
48. N.Lampri, I.Galani, G.Poulakou, et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2012;67(10):2424–2428.
49. L.E.Nicolle. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother. 2000;46(Suppl 1):35–39; discussion 63-35.
50. D.M.Musher, D.P.Griffith. Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect. Antimicrob Agents Chemother. 1974;6(6):708–711.
51. M.C.Nahata, B.A.Cummins, D.C.McLeod, et al. Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. Eur J Clin Pharmacol. 1982;22(3):281–284.
52. B.S.Lee, T.Bhuta, J.M.Simpson, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD003265.•• A comprehensive Cochrane review on the value of methenamine use as a prophylactic agent for UTI.
53. J.Jackson, T.A.Stamey. The Riker method for determining formaldehyde in the presence of methenamine. Invest Urol. 1971;9(2):124–129.
54. B.Vainrub, D.M.Musher. Lack of effect of methenamine in suppression of, or prophylaxis against, chronic urinary infection. Antimicrob Agents Chemother. 1977;12(5):625–629.
55. P.Nyren, L.Runeberg, A.I.Kostiala, et al. Prophylactic methenamine hippurate or nitrofurantoin in patients with an indwelling urinary catheter. Ann Clin Res. 1981;13(1):16–21.
56. S.Nilsson. Long-term treatment with methenamine hippurate in recurrent urinary tract infection. Acta Med Scand. 1975;198(1–2):81–85.
57. B.Norberg, A.Norberg, U.Parkhede, et al. Effect of short-term high-dose treatment with methenamine hippurate on urinary infection in geriatric patients with an indwelling catheter. IV. Clinical evaluation. Eur J Clin Pharmacol. 1979;15(5):357–361.
58. H.P.Til, R.A.Woutersen, V.J.Feron, et al. Two-year drinking-water study of formaldehyde in rats. Food Chem Toxicol. 1989;27(2):77–87.
59. M.L.Rummukainen, M.Makela, A.Noro, et al. Assessing prevalence of antimicrobial use and infections using the minimal data set in Finnish long-term care facilities. Am J Infect Control. 2013;41(4):e35–e37.
60. R.Kugathasan, M.Wootton, R.Howe. Cycloserine as an alternative urinary tract infection therapy: susceptibilities of 500 urinary pathogens to standard and alternative therapy antimicrobials. Eur J Clin Microbiol Infect Dis. 2014;33(7):1169–1172.
61. H.Welch, L.E.Putnam, W.A.Randall. Antibacterial activity and blood and urine concentrations of cycloserine, a new antibiotic, following oral administration. Antibiotic Med Clin Ther (New York). 1955;1(2):72–79.
62. P.Georgescu, E.Savuleanu, I.Daniello. The rythm of absorption and elimination of cycloserine as studied with the chromatographic technique. Scand J Respir Dis Suppl. 1970;71:61–63.
63. P.D.Hoeprich. Alanine: cycloserine antagonism. Iii. quantitative aspects and relation to heating of culture media. J Lab Clin Med. 1963;62:657–662.
64. J.M.Murdoch, J.D.Sleigh, S.C.Frazer. Cycloserine in treatment of infection of urinary tract. Br Med J. 1959;2(5159):1055–1058.
65. R.W.Fairbrother, G.Garrett. Treatment of urinary infections with cycloserine. Br Med J. 1960;2(5207):1191–1194.
66. C.Pelletier, P.Prognon, P.Bourlioux. Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother. 1995;39(3):707–713.
67. A.Sobke, M.Klinger, B.Hermann, et al. The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother. 2012;56(11):6021–6025.
68. K.G.Naber, H.Niggemann, G.Stein, et al. Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. BMC Infect Dis. 2014;14:628.
69. M.Kresken, B.Korber-Irrgang. In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany. Antimicrob Agents Chemother. 2014;58(11):7019–7020.
70. F.M.Wagenlehner, F.Munch, A.Pilatz, et al. Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. Antimicrob Agents Chemother. 2014;58(2):713–721.
71. D.M.Lyon, D.M.Dunlop. Mandelic acid in the treatment of urinary infections. Br Med J. 1935;2(3909):1096–1097.
72. J.C.Nickel. Management of urinary tract infections: historical perspective and current strategies: part 1–before antibiotics. J Urol. 2005;173(1):21–26.
73. J.M.Hamilton-Miller, W.Brumfitt. Methenamine and its salts as urinary tract antiseptics: variables affecting the antibacterial activity of formaldehyde, mandelic acid, and hippuric acid in vitro. Invest Urol. 1977;14(4):287–291.
74. D.Stickler, J.Dolman, S.Rolfe, et al. Activity of some antiseptics against urinary tract pathogens growing as biofilms on silicone surfaces. Eur J Clin Microbiol Infect Dis. 1991;10(5):410–415.
75. D.Mangin. Urinary tract infection in primary care. BMJ. 2010;340:c657.
76. T.C.Christiaens, M.De Meyere, G.Verschraegen, et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52(482):729–734.
77. E.Hummers-Pradier, A.M.Ohse, M.Koch, et al. Management of urinary tract infections in female general practice patients. Fam Pract. 2005;22(1):71–77.
78. G.M.Leydon, S.Turner, H.Smith, et al. Women’s views about management and cause of urinary tract infection: qualitative interview study. BMJ. 2010;340:c279.
79. I.Gagyor, J.Bleidorn, M.M.Kochen, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544.•• A randomized control trial on ibuprofen as a nonantibiotic alternative for management of UTI.
80. J.Bleidorn, E.Hummers-Pradier, G.Schmiemann, et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Ger Med Sci. 2016 ;14:Doc01. URN: urn:nbn:de:0183-0002286. doi:10.3205/000228.• Part 2 of a randomized control trial including a follow up analysis of the use of ibuprofen as a non-antibiotic alternative for UTI.